



## Theravance Biopharma to Participate in Upcoming Investor Conferences

November 19, 2025

DUBLIN, Nov. 19, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate in the following investor conferences in December 2025:

### 8<sup>th</sup> Annual Evercore Healthcare Conference

Location: Coral Gables, FL

Format: Fireside Chat

Date: Thursday, December 4, 2025

Time: 8:20-8:40 AM ET

[Webcast](#)

### Openheimer Movers in Rare Disease Summit

Location: New York, NY

Format: Panel Discussion - Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts

Date: Thursday, December 11, 2025

Time: 2:15-2:45 PM ET

Theravance will be available for one-on-one meetings during both events. Interested investors should contact their respective representatives to request meetings.

A live webcast of the Evercore presentation may also be accessed on the "[Events and Presentation](#)" page under the Investors section on [Theravance.com](#). A replay of the webcast will be archived on the Company's website for 30 days.

### About Theravance Biopharma

Theravance Biopharma, Inc.'s focus is to deliver *Medicines that Make a Difference*<sup>®</sup> in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI<sup>®</sup> (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

For more information, please visit [www.theravance.com](#).

THERAVANCE BIOPHARMA<sup>®</sup>, THERAVANCE<sup>®</sup> and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI<sup>®</sup> is a registered trademark of Viatris Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

Contact:

[investor.relations@theravance.com](mailto:investor.relations@theravance.com)

650-808-4045

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-upcoming-investor-conferences-302619765.html>

SOURCE Theravance Biopharma, Inc.